Lei Lei Wu is a news reporter for Endpoints News, specializing in reporting on drugs and biotechs. With a focus on the pharmaceutical industry, Lei Lei covers topics such as clinical trial results, FDA approvals, and biotech company developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lei Lei Wu's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly on biotechnology, pharmaceutical companies, gene therapy, clinical trials, and drug development. The majority of her articles are based on press releases and cite data.
Given this focus, she would likely be interested in receiving pitches related to new developments in biotechnology or pharmaceuticals backed by solid data or press releases. Pitches offering insights from experts within these fields regarding groundbreaking studies or significant advancements in drug development may resonate with her. Additionally, providing access to exclusive data or early access to important press releases could enhance the effectiveness of outreach efforts.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lei Lei Wu
Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for thalassemia and 5 starting Skysona for cerebral adrenoleukodystrophy. The company reported $10.6 million in Q3 revenue and expects $25 million next quarter, amid financial challenges.
Tune Therapeutics announced Thursday that New Zealand health authorities are allowing the company to study its experimental epigenetic editing therapy for …
By: Gene Tx
In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle disease can stabilize or improve outcomes …
By: Gene Tx
Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment.
Valora Therapeutics has $30 million to jump-start research on immunotherapies based on sugars — the kind that dots cell surfaces and helps devastating cancers evade immune …
Novocure announced Monday morning that its electrical field wearable device combined with chemotherapy passed a late-stage trial in pancreatic cancer, and the biotech now plans …
Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, suggesting that the therapy is durable beyond the …
By: Lei Lei Wu
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, showing over 60% fetal hemoglobin expression and resolved anemia. The company joins bluebird bio and Vertex/CRISPR Therapeutics in developing sickle cell treatments. One patient died from chemotherapy-related complications.
By: Gene Tx
SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson …
By: Lei Lei Wu
The FDA approved Checkpoint Therapeutics’ anti-PD-L1 antibody cosibelimab in a form of advanced skin cancer, the company announced Friday. The immune checkpoint drug will be marketed as Unloxcyt and will be administered as an IV infusion.
(833) 317-6278 
